DTIL Precision Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DTIL

Price (delayed)

$6.38

Market cap

$164.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.14

Enterprise value

$67.24M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome ...

Highlights
Precision Biosciences's quick ratio has surged by 111% YoY and by 7% QoQ
DTIL's EPS is up by 40% since the previous quarter and by 17% year-on-year
The company's net income has shrunk by 98% YoY but it rose by 4.6% QoQ
The company's equity has surged by 54% YoY but it fell by 18% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://precisionbiosciences.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of DTIL

DTIL stock price

How has the Precision Biosciences stock price performed over time
Intraday
5.63%
1 week
-7.8%
1 month
-16.38%
1 year
25.1%
YTD
53.37%
QTD
16%

Financial performance

How have Precision Biosciences's revenue and profit performed over time
Revenue
$45.07M
Gross profit
$45.07M
Operating income
-$39.11M
Net income
-$43.6M
Gross margin
100%
Net margin
-96.7%
DTIL's net margin has shrunk by 125% YoY but it is up by 28% QoQ
The company's net income has shrunk by 98% YoY but it rose by 4.6% QoQ
The operating margin is up by 43% since the previous quarter
Precision Biosciences's gross profit has increased by 32% from the previous quarter but it has decreased by 12% YoY

Price vs fundamentals

How does DTIL's price correlate with its fundamentals

Growth

What is Precision Biosciences's growth rate over time

Valuation

What is Precision Biosciences stock price valuation
P/E
N/A
P/B
2.07
P/S
3.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.49
DTIL's EPS is up by 40% since the previous quarter and by 17% year-on-year
The company's equity has surged by 54% YoY but it fell by 18% QoQ
DTIL's P/B is 18% below its 5-year quarterly average of 2.4 but 3.2% above its last 4 quarters average of 1.9
The P/S is 90% lower than the last 4 quarters average of 33.7 and 63% lower than the 5-year quarterly average of 8.9
Precision Biosciences's revenue has increased by 32% from the previous quarter but it has decreased by 12% YoY

Efficiency

How efficient is Precision Biosciences business performance
DTIL's ROS has dropped by 135% year-on-year but it is up by 28% since the previous quarter
Precision Biosciences's ROA has plunged by 129% YoY but it has increased by 8% from the previous quarter
Precision Biosciences's return on equity has shrunk by 122% YoY but it has increased by 16% QoQ
The return on invested capital has dropped by 110% year-on-year but it is up by 2.2% since the previous quarter

Dividends

What is DTIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DTIL.

Financial health

How did Precision Biosciences financials performed over time
Precision Biosciences's total assets is 112% more than its total liabilities
DTIL's current ratio has surged by 112% year-on-year and by 5% since the previous quarter
Precision Biosciences's quick ratio has surged by 111% YoY and by 7% QoQ
DTIL's debt is 63% lower than its equity
The company's equity has surged by 54% YoY but it fell by 18% QoQ
The debt to equity has declined by 38% year-on-year but it has increased by 19% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.